MERCK SANTE (Merck KGaA), Lyon, France
Realized turnaround of 50+ staff medical department to become fully appreciated as business partner in five therapeutic areas (oncology, neurology, fertility, endocrinology and general medicine), in its function as medical / scientific information provider and as RWE (Real World Evidence) data specialist.
MEDICAL DIRECTOR FRANCE (2019 to 2020)
Refocused activities before and especially during COVID-19 lockdown developing digital solutions.
¨ Designed and get approved Early Access Programme - ATU - BAVENCIO (Avelumab) in first line maintenance therapy of bladder cancer patients in alliance with Pfizer. First patient in: July 2020.
¨ Received approval by authorities of recommendation of use programme - RTU - with OVITRELLE (Choriogonadotropine alfa) in infertile male patients.
¨ Obtained MAVENCLAD (Cladribine) approval in highly active relapsing Multiple Sclerosis patients in May 2020 after an initial rejection in 2018.
¨ Reconfirmed Merck’s medical and scientific leadership position in fertility during lockdown period by establishing targeted scientific partnerships with fertility centers all over France.
¨ Coached and empowered the medical team, from first reports to new hires, to embrace the right attitude and to transform routine habits into a new and appropriate mindset focusing on the best possible support to health care providers and patients.